Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1994 Jul;68(7):4506–4513. doi: 10.1128/jvi.68.7.4506-4513.1994

First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs.

J P Langeveld 1, J I Casal 1, A D Osterhaus 1, E Cortés 1, R de Swart 1, C Vela 1, K Dalsgaard 1, W C Puijk 1, W M Schaaper 1, R H Meloen 1
PMCID: PMC236377  PMID: 8207825

Abstract

A synthetic peptide vaccine which protects dogs against challenge with virulent canine parvovirus is described. The amino acid sequence used was discovered in previous studies on the immunogenic properties of previously mapped antigenic sites and represents the amino-terminal region of viral protein VP2. As with marker vaccines, it is possible to discriminate between vaccinated dogs that have not been exposed to the virus and dogs that have been infected with the virus. The protective mechanism can be explained by a humoral response against the peptide aided by T-cell epitopes contained in the carrier protein used for peptide coupling. This is the first example of a synthetic peptide vaccine that induces protection in target animals.

Full text

PDF
4506

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agbandje M., McKenna R., Rossmann M. G., Strassheim M. L., Parrish C. R. Structure determination of feline panleukopenia virus empty particles. Proteins. 1993 Jun;16(2):155–171. doi: 10.1002/prot.340160204. [DOI] [PubMed] [Google Scholar]
  2. Appel M. J., Scott F. W., Carmichael L. E. Isolation and immunisation studies of a canine parco-like virus from dogs with haemorrhagic enteritis. Vet Rec. 1979 Aug 25;105(8):156–159. doi: 10.1136/vr.105.8.156. [DOI] [PubMed] [Google Scholar]
  3. Bansal G. P., Hatfield J. A., Dunn F. E., Kramer A. A., Brady F., Riggin C. H., Collett M. S., Yoshimoto K., Kajigaya S., Young N. S. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis. 1993 May;167(5):1034–1044. doi: 10.1093/infdis/167.5.1034. [DOI] [PubMed] [Google Scholar]
  4. Benjamini E., Torres J. V., Werner L. L., Malley A. Isolation and characterization of the neutralizable epitope of simian retrovirus-1 (SRV-1) and of the cell receptor for the virus. Adv Exp Med Biol. 1991;303:71–77. doi: 10.1007/978-1-4684-6000-1_9. [DOI] [PubMed] [Google Scholar]
  5. Bittle J. L., Houghten R. A., Alexander H., Shinnick T. M., Sutcliffe J. G., Lerner R. A., Rowlands D. J., Brown F. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature. 1982 Jul 1;298(5869):30–33. doi: 10.1038/298030a0. [DOI] [PubMed] [Google Scholar]
  6. Björling E., Broliden K., Bernardi D., Utter G., Thorstensson R., Chiodi F., Norrby E. Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6082–6086. doi: 10.1073/pnas.88.14.6082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carmichael L. E., Joubert J. C., Pollock R. V. Hemagglutination by canine parvovirus: serologic studies and diagnostic applications. Am J Vet Res. 1980 May;41(5):784–791. [PubMed] [Google Scholar]
  8. Chapman M. S., Rossmann M. G. Structure, sequence, and function correlations among parvoviruses. Virology. 1993 Jun;194(2):491–508. doi: 10.1006/viro.1993.1288. [DOI] [PubMed] [Google Scholar]
  9. Cortes E., San Martin C., Langeveld J., Meloen R., Dalsgaard K., Vela C., Casal I. Topographical analysis of canine parvovirus virions and recombinant VP2 capsids. J Gen Virol. 1993 Sep;74(Pt 9):2005–2010. doi: 10.1099/0022-1317-74-9-2005. [DOI] [PubMed] [Google Scholar]
  10. Cotmore S. F., Tattersall P. The autonomously replicating parvoviruses of vertebrates. Adv Virus Res. 1987;33:91–174. doi: 10.1016/s0065-3527(08)60317-6. [DOI] [PubMed] [Google Scholar]
  11. Dalsgaard K. Saponin adjuvants. 3. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in food-and-mouth disease vaccines. Arch Gesamte Virusforsch. 1974;44(3):243–254. [PubMed] [Google Scholar]
  12. DiMarchi R., Brooke G., Gale C., Cracknell V., Doel T., Mowat N. Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science. 1986 May 2;232(4750):639–641. doi: 10.1126/science.3008333. [DOI] [PubMed] [Google Scholar]
  13. Dietzschold B., Gore M., Marchadier D., Niu H. S., Bunschoten H. M., Otvos L., Jr, Wunner W. H., Ertl H. C., Osterhaus A. D., Koprowski H. Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J Virol. 1990 Aug;64(8):3804–3809. doi: 10.1128/jvi.64.8.3804-3809.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Doel T. R., Gale C., Do Amaral C. M., Mulcahy G., Dimarchi R. Heterotypic protection induced by synthetic peptides corresponding to three serotypes of foot-and-mouth disease virus. J Virol. 1990 May;64(5):2260–2264. doi: 10.1128/jvi.64.5.2260-2264.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Eugster A. K. Studies on canine parvovirus infections: development of an inactivated vaccine. Am J Vet Res. 1980 Dec;41(12):2020–2024. [PubMed] [Google Scholar]
  16. Fields C. G., Lloyd D. H., Macdonald R. L., Otteson K. M., Noble R. L. HBTU activation for automated Fmoc solid-phase peptide synthesis. Pept Res. 1991 Mar-Apr;4(2):95–101. [PubMed] [Google Scholar]
  17. Geerligs H. J., Kocken C. H., Drijfhout J. W., Weijer W. J., Bloemhoff W., Wilterdink J. B., Welling G. W., Welling-Wester S. Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice. J Gen Virol. 1990 Aug;71(Pt 8):1767–1774. doi: 10.1099/0022-1317-71-8-1767. [DOI] [PubMed] [Google Scholar]
  18. Goudsmit J., Back N. K., Nara P. L. Genomic diversity and antigenic variation of HIV-1: links between pathogenesis, epidemiology and vaccine development. FASEB J. 1991 Jul;5(10):2427–2436. doi: 10.1096/fasebj.5.10.2065891. [DOI] [PubMed] [Google Scholar]
  19. Hunt A. R., Short W. A., Johnson A. J., Bolin R. A., Roehrig J. T. Synthetic peptides of the E2 glycoprotein of Venezuelan equine encephalomyelitis virus. II. Antibody to the amino terminus protects animals by limiting viral replication. Virology. 1991 Nov;185(1):281–290. doi: 10.1016/0042-6822(91)90775-7. [DOI] [PubMed] [Google Scholar]
  20. Javaherian K., Langlois A. J., LaRosa G. J., Profy A. T., Bolognesi D. P., Herlihy W. C., Putney S. D., Matthews T. J. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science. 1990 Dec 14;250(4987):1590–1593. doi: 10.1126/science.1703322. [DOI] [PubMed] [Google Scholar]
  21. Kinnunen L., Huovilainen A., Pöyry T., Hovi T. Rapid molecular evolution of wild type 3 poliovirus during infection in individual hosts. J Gen Virol. 1990 Feb;71(Pt 2):317–324. doi: 10.1099/0022-1317-71-2-317. [DOI] [PubMed] [Google Scholar]
  22. Kit M., Kit S., Little S. P., Di Marchi R. D., Gale C. Bovine herpesvirus-1 (infectious bovine rhinotracheitis virus)-based viral vector which expresses foot-and-mouth disease epitopes. Vaccine. 1991 Aug;9(8):564–572. doi: 10.1016/0264-410x(91)90243-y. [DOI] [PubMed] [Google Scholar]
  23. Koolen M. J., Borst M. A., Horzinek M. C., Spaan W. J. Immunogenic peptide comprising a mouse hepatitis virus A59 B-cell epitope and an influenza virus T-cell epitope protects against lethal infection. J Virol. 1990 Dec;64(12):6270–6273. doi: 10.1128/jvi.64.12.6270-6273.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Langeveld J. P., Casal J. I., Vela C., Dalsgaard K., Smale S. H., Puijk W. C., Meloen R. H. B-cell epitopes of canine parvovirus: distribution on the primary structure and exposure on the viral surface. J Virol. 1993 Feb;67(2):765–772. doi: 10.1128/jvi.67.2.765-772.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lerner R. A., Green N., Alexander H., Liu F. T., Sutcliffe J. G., Shinnick T. M. Chemically synthesized peptides predicted from the nucleotide sequence of the hepatitis B virus genome elicit antibodies reactive with the native envelope protein of Dane particles. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3403–3407. doi: 10.1073/pnas.78.6.3403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. López de Turiso J. A., Cortés E., Martínez C., Ruiz de Ybáez R., Simarro I., Vela C., Casal I. Recombinant vaccine for canine parvovirus in dogs. J Virol. 1992 May;66(5):2748–2753. doi: 10.1128/jvi.66.5.2748-2753.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. López de Turiso J. A., Cortés E., Ranz A., García J., Sanz A., Vela C., Casal J. I. Fine mapping of canine parvovirus B cell epitopes. J Gen Virol. 1991 Oct;72(Pt 10):2445–2456. doi: 10.1099/0022-1317-72-10-2445. [DOI] [PubMed] [Google Scholar]
  28. Martyn J. C., Davidson B. E., Studdert M. J. Nucleotide sequence of feline panleukopenia virus: comparison with canine parvovirus identifies host-specific differences. J Gen Virol. 1990 Nov;71(Pt 11):2747–2753. doi: 10.1099/0022-1317-71-11-2747. [DOI] [PubMed] [Google Scholar]
  29. Martínez C., Dalsgaard K., López de Turiso J. A., Cortés E., Vela C., Casal J. I. Production of porcine parvovirus empty capsids with high immunogenic activity. Vaccine. 1992;10(10):684–690. doi: 10.1016/0264-410x(92)90090-7. [DOI] [PubMed] [Google Scholar]
  30. Martínez M. A., Dopazo J., Hernández J., Mateu M. G., Sobrino F., Domingo E., Knowles N. J. Evolution of the capsid protein genes of foot-and-mouth disease virus: antigenic variation without accumulation of amino acid substitutions over six decades. J Virol. 1992 Jun;66(6):3557–3565. doi: 10.1128/jvi.66.6.3557-3565.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Meunier P. C., Cooper B. J., Appel M. J., Lanieu M. E., Slauson D. O. Pathogenesis of canine parvovirus enteritis: sequential virus distribution and passive immunization studies. Vet Pathol. 1985 Nov;22(6):617–624. doi: 10.1177/030098588502200617. [DOI] [PubMed] [Google Scholar]
  32. Muir S., Weintraub J. P., Hogle J., Bittle J. L. Neutralizing antibody to Mengo virus, induced by synthetic peptides. J Gen Virol. 1991 May;72(Pt 5):1087–1092. doi: 10.1099/0022-1317-72-5-1087. [DOI] [PubMed] [Google Scholar]
  33. Parrish C. R., Aquadro C. F., Carmichael L. E. Canine host range and a specific epitope map along with variant sequences in the capsid protein gene of canine parvovirus and related feline, mink, and raccoon parvoviruses. Virology. 1988 Oct;166(2):293–307. doi: 10.1016/0042-6822(88)90500-4. [DOI] [PubMed] [Google Scholar]
  34. Parrish C. R. Emergence, natural history, and variation of canine, mink, and feline parvoviruses. Adv Virus Res. 1990;38:403–450. doi: 10.1016/S0065-3527(08)60867-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Pavlov A. V., Rybakov S. S., Ivaniushchenkov V. N., Chepurkin A. V., Petrov V. N., Driagalin N. N., Burdov A. N. Zashchita ot iashchura estestvenno-vospriimchivykh zhivotnykh lineinym polimerom sinteticheskogo peptida. Bioorg Khim. 1991 Jul;17(7):953–963. [PubMed] [Google Scholar]
  36. Pollock R. V., Carmichael L. E. Maternally derived immunity to canine parvovirus infection: transfer, decline, and interference with vaccination. J Am Vet Med Assoc. 1982 Jan 1;180(1):37–42. [PubMed] [Google Scholar]
  37. Pollock R. V. Experimental canine parvovirus infection in dogs. Cornell Vet. 1982 Apr;72(2):103–119. [PubMed] [Google Scholar]
  38. Posthumus W. P., Lenstra J. A., van Nieuwstadt A. P., Schaaper W. M., van der Zeijst B. A., Meloen R. H. Immunogenicity of peptides simulating a neutralization epitope of transmissible gastroenteritis virus. Virology. 1991 May;182(1):371–375. doi: 10.1016/0042-6822(91)90684-4. [DOI] [PubMed] [Google Scholar]
  39. Reed A. P., Jones E. V., Miller T. J. Nucleotide sequence and genome organization of canine parvovirus. J Virol. 1988 Jan;62(1):266–276. doi: 10.1128/jvi.62.1.266-276.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Rhode S. L., 3rd Nucleotide sequence of the coat protein gene of canine parvovirus. J Virol. 1985 May;54(2):630–633. doi: 10.1128/jvi.54.2.630-633.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Rimmelzwaan G. F., Carlson J., UytdeHaag F. G., Osterhaus A. D. A synthetic peptide derived from the amino acid sequence of canine parvovirus structural proteins which defines a B cell epitope and elicits antiviral antibody in BALB c mice. J Gen Virol. 1990 Nov;71(Pt 11):2741–2745. doi: 10.1099/0022-1317-71-11-2741. [DOI] [PubMed] [Google Scholar]
  42. Rimmelzwaan G. F., Juntti N., Klingeborn B., Groen J., UytdeHaag F. G., Osterhaus A. D. Evaluation of enzyme-linked immunosorbent assays based on monoclonal antibodies for the serology and antigen detection in canine parvovirus infections. Vet Q. 1990 Jan;12(1):14–20. doi: 10.1080/01652176.1990.9694236. [DOI] [PubMed] [Google Scholar]
  43. Saikawa T., Anderson S., Momoeda M., Kajigaya S., Young N. S. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol. 1993 Jun;67(6):3004–3009. doi: 10.1128/jvi.67.6.3004-3009.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Saliki J. T., Mizak B., Flore H. P., Gettig R. R., Burand J. P., Carmichael L. E., Wood H. A., Parrish C. R. Canine parvovirus empty capsids produced by expression in a baculovirus vector: use in analysis of viral properties and immunization of dogs. J Gen Virol. 1992 Feb;73(Pt 2):369–374. doi: 10.1099/0022-1317-73-2-369. [DOI] [PubMed] [Google Scholar]
  45. Shafferman A., Jahrling P. B., Benveniste R. E., Lewis M. G., Phipps T. J., Eden-McCutchan F., Sadoff J., Eddy G. A., Burke D. S. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7126–7130. doi: 10.1073/pnas.88.16.7126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Snijders A., Benaissa-Trouw B. J., Oosterlaken T. A., Puijk W. C., Posthumus W. P., Meloen R. H., Boere W. A., Oosting J. D., Kraaijeveld C. A., Snippe H. Identification of linear epitopes on Semliki Forest virus E2 membrane protein and their effectiveness as a synthetic peptide vaccine. J Gen Virol. 1991 Mar;72(Pt 3):557–565. doi: 10.1099/0022-1317-72-3-557. [DOI] [PubMed] [Google Scholar]
  47. Steinhauer D. A., Holland J. J. Rapid evolution of RNA viruses. Annu Rev Microbiol. 1987;41:409–433. doi: 10.1146/annurev.mi.41.100187.002205. [DOI] [PubMed] [Google Scholar]
  48. Tanaka Y., Zeng L., Shiraki H., Shida H., Tozawa H. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization. J Immunol. 1991 Jul 1;147(1):354–360. [PubMed] [Google Scholar]
  49. Trirawatanapong T., Chandran B., Putnak R., Padmanabhan R. Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody. Gene. 1992 Jul 15;116(2):139–150. doi: 10.1016/0378-1119(92)90509-N. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Trudel M., Nadon F., Séguin C., Binz H. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. Virology. 1991 Dec;185(2):749–757. doi: 10.1016/0042-6822(91)90546-n. [DOI] [PubMed] [Google Scholar]
  51. Tsao J., Chapman M. S., Agbandje M., Keller W., Smith K., Wu H., Luo M., Smith T. J., Rossmann M. G., Compans R. W. The three-dimensional structure of canine parvovirus and its functional implications. Science. 1991 Mar 22;251(5000):1456–1464. doi: 10.1126/science.2006420. [DOI] [PubMed] [Google Scholar]
  52. Tullis G. E., Burger L. R., Pintel D. J. The trypsin-sensitive RVER domain in the capsid proteins of minute virus of mice is required for efficient cell binding and viral infection but not for proteolytic processing in vivo. Virology. 1992 Dec;191(2):846–857. doi: 10.1016/0042-6822(92)90260-v. [DOI] [PubMed] [Google Scholar]
  53. van Oirschot J. T., Gielkens A. L., Moormann R. J., Berns A. J. Marker vaccines, virus protein-specific antibody assays and the control of Aujeszky's disease. Vet Microbiol. 1990 Jun;23(1-4):85–101. doi: 10.1016/0378-1135(90)90139-m. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES